Table 3.

Moderating effects of the comparator SGA on annualized rate ratios of treatment emergent tardive dyskinesia in studies comparing FGAs vs. SGAs

SGA comparator in FGA study	Amisulpride	Clozapine	Olanzapine	Quetiapine	Risperidone	Ziprasidone
Aripiprazole	Q=5.75, p=0.017	Q=7.14, p=0.008	Q=5.04, p=0.025	Q=4.24, p=0.039	Q=11.27, p=0.004	Q=8.84, p=0.003
Amisulpride	‐	Q=0.07, p=0.94	Q=0.65, p=0.42	Q=1.84, p=0.17	Q=2.84, p=0.28	Q=0.49, p=0.49
Clozapine		‐	Q=1.72, p=0.19	Q=2.72, p=0.13	Q=2.52, p=0.28	Q=0.58, p=0.45
Olanzapine			‐	Q=6.12, p=0.013	Q=8.5, p=0.015	Q=3.6, p=0.06
Quetiapine				‐	Q=4.15, p=0.15	Q=0.608, p=0.43
Risperidone					‐	Q=2.58, p=0.27

Significant effects are highlighted in bold prints. FGAs – first‐generation antipsychotics, SGAs – second‐generation antipsychotics